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a b s t r a c t
Porcine circovirus type 2 (PCV2) is the primary causative agent of porcine circovirus-associated diseases
(PCVAD). It has been shown that the ubiquitin-proteasome system (UPS) is correlated with viral
infection, but its role in PCV2 replication remains unknown. In the present study, we explored the
interplay between PCV2 replication and the UPS in PK15 cells and found that treatment with a
proteasome inhibitor (MG132 and lactacystin) signiﬁcantly decreased the PCV2 titer at the early
infection stage. We further revealed that inhibition of the UPS did not affect virus entry but decreased
viral protein expression and RNA transcription potentially in a cell cycle-dependent manner. PCV2
infection has little effect on the chymotrypsin-like activity, and the gene-silencing of ubiquitin reduced
the PCV2 titer, which indicates that the effective replication of PCV2 may be related to protein
ubiquitination. Taken together, our data suggested that PCV2 replication requires the UPS machinery,
which may represent a potential antiviral target against PCV2.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Porcine circovirus type 2 (PCV2), which belongs to the genus
circovirus of the family Circoviridae, is the most important pathogen
among the porcine circovirus-associated diseases (PCVAD), including
postweaning multisystemic wasting syndrome (PMWS) (Segales
et al., 1997), porcine dermatitis and nephropathy syndrome (PDNS)
(Ramos-Vara et al., 1997), reproductive failure, porcine respiratory
disease complex (PRDC), granulomatous enteritis, necrotizing lym-
phadenitis (Chae, 2005), and acute pulmonary edema (APE) (Cino-
Ozuna et al., 2011). The main target cells of PCV2 are considered to be
macrophage/monocyte-lineage cells and other antigen-presenting
cells (Rosell et al., 1999). PMWS is associated with swine immuno-
suppressive or immunodepressive diseases, which pave the way for
secondary infection byMycoplasma hyopneumoniae (Opriessnig et al.,
2004), porcine reproductive and respiratory syndrome virus (Harms
et al., 2001), and porcine parvovirus (Allan et al., 1999).
The ubiquitin-proteasome system (UPS) coupled with the auto-
phagy-lysosome system is the major protein degradation pathway in
eukaryotic cells (Wong and Cuervo, 2010). The UPS, which regulates
many protein targets within cells, plays an important role in a variety
of biological processes. The cell cycle-regulated proteins, including
cyclins (Glotzer et al., 1991), p27 (Pagano et al., 1995), and p35 (Patrick
et al., 1998), are modulated by ubiquitination. The proteasome de-
grades the majority of the cellular proteins and generates most
peptides presented on major histocompatibility complex (MHC) class
I molecules (Rock et al., 1994). In addition, ubiquitin-activating enzyme
E1 is required for MHC class I antigen presentation (Michalek et al.,
1993). Additionally, nuclear factor-kappa B (NF-κB) is activated after
IκBα is phosphorylated and consequently ubiquitinated (Chen et al.,
1995), and the p105 NF-κB precursor for the p50 subunit also requires
the proteasome and ubiquitin conjugation (Palombella et al., 1994). In
cultured rat hippocampal neurons, the synaptic activity regulates the
postsynaptic composition and signaling through the UPS (Ehlers,
2003). These above-mentioned studies demonstrate that the UPS
not only plays a role in the complete degradation of polypeptides
but also regulates the cell cycle, MHC I molecule-mediated antigen
processing, and signaling pathways. Furthermore, the UPS also plays
major roles in cell viability, DNA repair, protein synthesis, and stress
response (Ciechanover and Iwai, 2004; Jentsch et al., 1987; Varshavsky,
2005).
Because the UPS has a vital role in many fundamental cellular
processes, many viruses have reprogrammed the machinery accord-
ing to their needs. Evidence shows that the UPS regulates the
replication of rotavirus (Lopez et al., 2011), human immunodeﬁ-
ciency virus (Klinger and Schubert, 2005), Coxsackievirus B3 (Luo
et al., 2003), ﬂavivirus (Fernandez-Garcia et al., 2011), and vaccinia
virus (Satheshkumar et al., 2009). In addition, Liu et al. demonstrated
that porcine p53-induced RING-H2 (pPirh2), an E3 ubiquitin ligase,
interacts with the ORF3 protein of PCV2 (Liu et al., 2007). We also
found that the UPS-associated proteins are differently expressed in
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PCV2-infected porcine alveolar macrophages (Cheng et al., 2012).
However, it is unknown whether the replication of PCV2 requires
the UPS.
In the present study, we demonstrated that the inhibition of the
UPS suppresses PCV2 replication at the early infection stage through
the degradation of viral DNA copies, protein expression, and viral
transcription potentially in a cell cycle-dependent manner. These
results illustrate an important role of UPS in the regulation of the
early stages of PCV2 replication.
Results
Effects of proteasome inhibitors on PCV2 infection in PK15 cells
To determine whether the UPS is involved in PCV2 replication, the
speciﬁc proteasome inhibitors MG132 and lactacystin were used to
explore the effect of UPS inhibition on PCV2 titer. We ﬁrst evaluated
the cell viability of MG132- and lactacystin-treated cells. The results
showed that the cell survival was greater than 80% after treatment
with MG132 or lactacystin at concentrations up to 10 μM (Fig. 1A).
We then assessed the effects of MG132 and lactacystin on the PCV2
titer. The cell supernatants were collected at 12 hours post infection
(hpi), and the viral DNA copies were determined by absolute
quantitative real-time PCR. Compared with DMSO-treated PK15 cells,
MG132 (5 μM) inhibited the PCV2 titer in the cultured cells by 20.91%,
and lactacystin (10 μM) inhibited the PCV2 titer by 28.09% (Fig. 1B).
These data indicate that UPS regulates the early stages of PCV2
replication in PK15 cells.
Effects of proteasome inhibitors on different stages of PCV2 infection
To identify which step(s) in the virus lifecycle are targeted by
proteasome inhibitors, we ﬁrst quantiﬁed the viral DNA copies after
applying the inhibitors at different time points. After the cells were
incubated for 12 hpi, the supernatants were subjected to a viral copy
assay. As shown in Fig. 2A, exposure to the inhibitors at 2 hpi
signiﬁcantly inhibited the number of viral DNA copies, and this
inhibition was almost the same as that observed when the inhibitors
were added at 2 hpi or 0 hpi. This ﬁnding suggests that the inhi-
bition of viral replication by the proteasome inhibitors is likely not
dependent on the blockade of viral entry into the host cells.
We further observed the effects of MG132 or lactacystin on viral
protein expression and RNA transcription. A western blot analysis
showed that both proteasome inhibitors (MG132 and lactacystin)
decreased the expression of the PCV2 ORF2-encoded capsid protein in
a dose-dependent manner (Fig. 2B). In addition, the transcriptional
levels of ORF2 were reduced in MG132-treated cells compared to the
levels observed in DMSO-treated cells (Fig. 2C). Taken together, these
results indicate that the proteasome inhibitors decrease the number of
viral DNA copies through suppression of viral protein expression and
RNA transcription at the early infection stage.
Proteasome inhibitors induce G2/M phase arrest
As the smallest DNA virus infecting mammals, PCV2 replication
depends on cellular enzymes expressed during the S phase of cells
growth (Tischer et al., 1987). Experimental evidence shows that the
UPS plays an important role in the regulation of the cell cycle,
including the induction of S, G2/M arrest, and apoptosis (Han et al.,
2009). To investigate whether the downregulation of the PCV2 titer
is due to the effect of proteasome inhibitors on cell cycle progression,
a ﬂow cytometric analysis was performed based on the DNA content
observed in nuclei stained with propidium iodide (PI, Sigma-Aldrich).
As shown in Fig. 3, the percentages of cells in the sub-G1 phase and S
phase were approximately 1% and 30%, respectively, and these
percentages were not signiﬁcantly inﬂuenced by treatment with
MG132. However, a dose-dependent increase in the cell population
at the G2/M phase was observed after treatment with MG132, and
the increased cell populations after this treatment ranged from
44.6979.84% to 57.4575.93%. Additionally, the percentages of cells
in the G0/G1 phase, which ranged from 22.83711.60% to 12.227
7.90%, were signiﬁcantly decreased in a dose-dependent manner
with MG132 (Fig. 3B). A similar trend was also found in the PK15
cells treated with lactacystin (Fig. 3C). Taken together, the results
reveal that proteasome inhibitors inﬂuence the cell cycle progression
by prolonging the G2/M phase, which suggests that inhibition of the
UPS may suppress the replication of PCV2 in a cell cycle-dependent
manner.
Proteasome activity in PCV2-infected PK15 cells
There are two successive steps involved in protein degradation: the
target protein substrates are ubiquitinated through their covalent
attachment to ubiquitin, and ubiquitinated proteins are degraded in
Fig. 1. Effects of proteasome inhibitors on PCV2 infection in PK15 cells. (A) Cell viability of inhibitor-treated PK15 cells. PK15 cells were treated with proteasome inhibitors
(MG132 and lactacystin) at the indicated concentrations. The cell viability after treatment was assessed using the MTT assay. The MTT absorbance values of the DMSO-treated
cells were deﬁned as 100% survival. The values are the means7SD (n¼5). (B) PCV2 titers in the inhibitor-treated PK15 cells. After infection with PCV2, the PK15 cells were
incubated with DMEM containing the inhibitors. The supernatant was collected at 12 hpi, and the virus titer was determined through absolute quantitative real-time PCR.
The statistical analysis was performed using SPSS Statistics 17.0: signiﬁcance was deﬁned as Po0.05 (*), and high signiﬁcance was deﬁned as Po0.01(**).
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the 26S proteasome. To elucidate the role of the UPS in PCV2 infection,
we investigated the proteasome activity in PK15 cells after PCV2
infection. The PK15 cells were ﬁrst infected with PCV2 and then
incubated with a ﬂuorogenic proteasome peptide substrate, and PK15
cells incubated with MG132 or lactacystin were used as the positive
control. The cell medium was then collected for measurement of the
chymotrypsin-like (CT-like) activity (Luo et al., 2003). The results show
that PCV2 infection did not affect the proteasomal CT-like activity,
whereas treatments with MG132 or lactacystin inhibited 40% of the
proteasomal CT-like activity in the PK15 cells (Fig. 4). This observation
suggests that protein ubiquitination may play a role in the PCV2
replication.
Knockdown of ubiquitin by siRNA reduces PCV2 infection
The ubiquitination of cellular proteins starts with their covalent
conjugation to ubiquitin (Hershko and Ciechanover, 1992). To inves-
tigate the role of ubiquitination in PCV2 replication, we used an
ubiquitin-speciﬁc siRNA (S117) to knockdown the expression of the
Sus Scrofa ubiquitin B gene (GI: 156105184). As shown in Fig. 5, the
viral DNA copies were reduced to 16.6% in the ubiquitin siRNA-
transfected cells compared to the negative control (NC). These results
suggest that protein ubiquitination may be a critical process during
the PCV2 lifecycle.
Discussion
The UPS plays an important role in the degradation of intracellular
proteins and regulates the cellular signaling pathway (Mukhopadhyay
and Riezman, 2007). Many viruses have manipulated the UPS for their
needs (Randow and Lehner, 2009; Shackelford and Pagano, 2005). For
example, the UPS has been suggested to be required for viral immune
evasion, for viral maturation and viral progeny release, for efﬁcient
viral replication, and for reactivation of virus from latency (Gao and
Luo, 2006). In the present study, we show that treatment with
proteasome inhibitors (MG132 and lactacystin) leads to a reduction
in viral activity, as determined by decreases in the number of viral
DNA copies, viral protein synthesis, and RNA transcription, likely in a
cell cycle-dependent manner at the early viral infection stage. We
further show that PCV2 infection has little effect on proteasomal
activity and that the depletion of ubiquitin with siRNA reduces the
genome copies of PCV2, which indicates that PCV2 infection may be
correlated with protein ubiquitination.
A previous study showed that the inhibition of UPS impairs the
viral infection cycle (Raaben et al., 2010). For instance, MG132 affects
hepatitis E virus replication likely through the inhibition of viral
transcription and/or translation without a signiﬁcant effect on
cellular translation (Karpe and Meng, 2012). Wang et al. (2011)
demonstrated that cellular inhibitor of apoptosis protein 2 (cIAP2)
can signiﬁcantly reduce the levels of hepatitis B virus DNA replication
via acceleration of the UPS-mediated decay of the polymerase. In the
present study, we examined the effects of the proteasome inhibitors
MG132 and lactacystin on PCV2 replication and found that the
inhibition of the UPS reduces the number of viral DNA copies at
12 hpi (Fig. 1B). This ﬁnding suggests that the UPS is required for the
early stage of PCV2 replication.
The UPS plays an important role in the different stages of the
virus lifecycle, including viral entry, gene transcription, protein
synthesis, assembly, and viral progeny release (Gao and Luo,
Fig. 2. Proteasome inhibition decreases ORF2 expression and viral RNA transcription in PCV2-infected PK15 cells. (A) Proteasome inhibitors were added to PK15 at 2 hpi,
0 hpi and 2 hpi. The supernatants were harvested at 12 hpi, and absolute quantitative real-time PCR was performed. nPo0.05 and nnPo0.01 compared with DMSO-treated
cells. M and L indicate treatment with MG132 and lactacystin, respectively; 2, 0, and 2 indicate the time at which the inhibitor was added. The following statistical
differences were found between the groups: (a and b) M-2 and M2 compared with M0: pM-2/M0¼0.854, pM2/M0¼0.837, (c and d) L-2 and L2 compared with L0: pL-2/L0¼0.88,
pL2/L0¼0.564. (B) After PCV2 infection, PK15 cells were incubated in the DMEM containing DMSO or inhibitors. The cell lysate was collected at 12 hpi, and a western blot
assay for the detection of viral capsid protein ORF2 and ACTB was performed. The protein levels were quantiﬁed by densitometric analysis using Image-Pro Plus (version 4.5)
and normalized with the ACTB levels. (C) The total cellular RNA of PCV2-infected PK15 cells treated with DMSO or MG132 was subjected to real-time RT-PCR analysis.
The samples were normalized using the DMSO-treated PK15 cells as calibrators and GAPDH as the reference gene.
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2006). Proteasome inhibitors reduce viral RNA synthesis and
capsid protein expression of Coxsackievirus B3 infection (Si et al.,
2008), and appear to not only impair entry but also RNA synthesis
and subsequent protein expression of different coronavirus
(Raaben et al., 2010). Ubiquitin-mediated proteolysis is required
for the transcriptional activation of synthetic herpes simplex viral
VP16 transcription activators (Zhu et al., 2004). Ubiquitin ligase
Nedd4 can interact with the Gag protein of human T-cell leukemia
virus type 1 (HTLV-1) and that this interaction plays a critical role
in HTLV-1 budding (Sakurai et al., 2004). MG132 affects Inﬂuenza A
virus (IAV) infection at a postfusion step (Widjaja et al., 2010). Tat, a
potent transactivator encoded by the human immunodeﬁciency
virus type 1 (HIV-1), is regulated by ubiquitination to stimulate its
transcriptional properties (Bres et al., 2003). In the present study,
we found that the proteasome inhibitors signiﬁcantly inhibited the
viral transcription and protein expression. Replication of the PCV2
requires the Rep protein complex which consists of 2 viral proteins
Rep and Rep0, and Rep0 is a spliced form of the Rep mRNA (Faurez et
al., 2009). Thus, it was not surprising that treatment of PCV2-
infected cells with proteasome inhibitors reduced viral transcription
as well as protein expression.
Proteasome inhibitors regulate the cell cycle progression. In the
present study, the inhibitors were found to arrest the cell cycle
progression of PK15 cells at the G2/M phase, which is consistent
with the results of a previous study (Zanotto-Filho et al., 2010).
PCV2 replication starts from the entry of the single-stranded DNA
genome into the nucleus, which resulted in their inclusion in the
daughter nuclei at the end of mitosis. Viral replication is initiated
by the binding of rep protein complex to the stem loop structure
and depends on the cellular DNA polymerase expressed during the
S phase (Tischer et al., 1987). Although the proteasome inhibitors
have no effect on the S phase at the early infection stage, the cell
cycle is a complex process that involves numerous regulatory
proteins. G2/M arrest inhibits cell cycle progression, which may
inﬂuence the entry of the PCV2 genome into the nucleus and the
expression of cellular enzymes. These ﬁndings indicate that
proteasome inhibitors regulate the replication of PCV2 likely in a
cell cycle-dependent manner.
Ubiquitination and proteasome degradation are important pro-
cesses regulated by the UPS (Ciechanover, 1994). The ﬁndings obtained
in the present study, which demonstrate that PCV2 infection appears
to have no effect on the proteasomal activity and that the knockdown
of ubiquitin reduces the viral titer, highlight the possibility that the
PCV2 replication are modulated via protein ubiquitination. The
ubiquitination of cellular proteins is required for the effective replica-
tion of Coxsackievirus B3 (Si et al., 2008). In addition, Liu et al.
demonstrated that the ORF3 protein of PCV2 decreases the expression
of pPirh2, an E3 ubiquitin ligase, and increases the expression of p53
(Liu et al., 2007). The interaction between ubiquitination and viral
infection requires further study.
In conclusion, we have shown that proteasome inhibitors (MG132
and lactacystin) reduce PCV2 infectivity, as demonstrated by decreases
in the number of viral genomic copies, viral protein expression, and
RNA transcription, at the early viral infection stage. In addition, the
role of the UPS in PCV2 replication may be associated with protein
ubiquitination. Our results suggest that the UPS may be a novel anti-
viral target against PCV2.
Fig. 3. Effects of proteasome inhibitors on the cell cycle distribution in PK15 cells.
(A) Flow cytometry analysis of cells through PI staining. Percentages of the MG132-
(B) and lactacystin- (C) treated PK15 cells in each phase of the cell cycle.
Fig. 4. Proteasome activity in PCV2-infected PK15 cells. PK15 cells were infected
with PCV2 or DMEM, and cells treated with MG132 and lactacystin were used as
the positive controls. The cell lysates were collected, and the proteasomal activity
was measured using the ﬂuorogenic proteasome substrate SLLVY-AMC (Merck).
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Materials and methods
Virus and cells
The PK15 cell line, free of PCV, was maintained in Dulbecco's
Modiﬁed Eagle's Media (DMEM) supplemented with 10% heat-
inactivated newborn calf serum (NCS) at 37 1C in a humidiﬁed 5%
CO2 incubator. PCV2 (GI: 225322671), which was originally iso-
lated from a pig farm in the Hubei Province of China, was cultured
on PK15 cell lines.
Virus infection
PK15 cells were seeded in cell culture plates, grown to 50–60%
conﬂuence, and then infected at a multiplication of infection (MOI) of
10 with PCV2 or mock-infected with DMEM for 1 h in serum-free
DMEM. The cells were then washed with PBS and cultured in DMEM
supplemented with 2% NCS. For the inhibition experiments, PK15
cells were infected with PCV2 and incubated with DMEM containing
the inhibitors at the designed time.
Cell viability assay
The MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl-2H-tetra-
zolium bromide) assay was performed to determine the cell viability
as previously described (Li et al., 2012). Brieﬂy, the cells were
inoculated on a 96-well plate and incubated with different concen-
trations of the inhibitors. The cells were then incubated with MTT
solution for 4 h and collected. The absorbance was measured at a
wavelength of 490 nm using an ELISA reader.
Quantitative real-time PCR
The total viral DNA from the PCV2-infected PK15 cells was
extracted using a Virus DNA Extraction Kit (Omega). To quantify the
viral DNA copies, absolute quantitative real-time PCR was performed
using the FastStart Universal Probe Master (Rox) (Roche) in a total
volume of 20 μL on an ABI prism 7500 (Applied Biosystems). The cycle
conditions were 2 min at 50 1C, 10 min at 95 1C, and 40 cycles of 95 1C
for 15 s and 60 1C for 1 min. For the standard curve, serial dilutions
of a plasmid that was constructed by inserting the PCV2 gene (GI:
225322671) into the pMD™18-T vector (TAKARA) were used to
quantify the virus genomic copy number (Yang et al., 2012).
Relative quantitative real-time RT-PCR was performed to evaluate
the RNA transcription of ORF2. The total cell RNA at 12 hpi was
extracted using the Trizol RNA extraction reagent (Invitrogen). The
primers, which are shown in Table 1, were designed using the Beacon
Designer 7.9 analysis software. The RNA samples were treated with
DNase I for 60 min at 37 1C. The cDNA was produced by the reverse
transcription (RT) of 1 μg of RNA using random primers (Roche)
according to the manufacturer's protocols. Quantitative real-time
PCR was performed using a total volume of 20 μL on a LightCycler
480 (Roche) instrument according to the instructions provided by the
manufacturer of the FastStart Universal SYBR Green Master (Roche).
The cycle conditions were 30 s at 95 1C and 40 cycles of 95 1C for 10 s,
60 1C for 5 s, and 72 1C for 10 s (Cheng et al., 2012). Each sample was
run in triplicate. The sample was normalized to DMSO-treated PK15
cells as the reference sample, and GAPDH or β-actin were used as the
reference gene.
Western blotting
The PK15 cells were lysed in a lysis buffer containing 50 mM
Tris–HCl (pH 6.8), 10% glycerol, and 2% SDS. The whole cell lysate
Fig. 5. Knockdown of ubiquitin expression by siRNA reduces PCV2 DNA copies. PK15 cells were transiently transfected with the ubiquitin siRNA or NC RNA and then infected
with PCV2. The cell lysates were collected at 12 hpi. (A) A western blot assay was performed using anti-ubiquitin and anti-ACTB antibodies. (B) The supernatants were
collected at 12 hpi, and the viral DNA copies were determined by absolute quantitative real-time PCR. nPo0.05 compared to the number of viral DNA copies in the
NC-transfected cells.
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extracts were then diluted in 5 sample buffer and boiled for
10 min. Each sample was subjected to 12% SDS-PAGE and then
transferred to nitrocellulose membranes (Millipore). After block-
ing with 1% (w/v) BSA-TBST (20 mM Tris‐HCl (pH 7.4), 150 mM
NaCl, and 0.05% Tween-20) for 2 h at room temperature, the
membranes were incubated with primary antibodies to ORF2
(prepared in our laboratory), ubiquitin (ubi, Bioss), and β-actin
(ACTB, Beyotime) at room temperature for 2 h and then with HRP-
conjugated secondary antibodies. The membranes were then
visualized using the SuperSignal West Pico Luminal kit (Pierce).
Cell cycle analysis by ﬂow cytometry
The cell cycle distributions and sub-G1 cell populations were
measured by staining the DNA with PI as previously described (Han
et al., 2009). Brieﬂy, the inhibitor- or DMSO-treated PCV2-infected
PK15 cells were washed with ice-cold phosphate-buffered saline (PBS)
and ﬁxed in 70% ethanol at 20 1C. After washing with PBS, the cells
were resuspended in PBS containing 20 μg/mL RNase A and 50 μg/mL
PI and incubated at room temperature for 30 min in the dark. The
nuclear DNA content was examined using a FACS Calibur system (BD
Biosciences, USA) with the Cell Quest software. The results were
representative of at least three independent experiments.
Ubiquitin siRNA transfection
The PK15 cells were grown to 30–50% conﬂuence and then
transiently transfected with ubiquitin-speciﬁc siRNA using Lipofecta-
mine 2000 according to the manufacturer suggested protocol. A nega-
tive control (NC) siRNA was used as a control. The silencing efﬁciency
was detected by immunoblot analyses using an anti-ubiquitin anti-
body. Fifteen hours after transfection, the cells were infected with
PCV2 as previously described.
Statistical analysis
The results are presented as the means7standard deviations
(SD). The statistical analysis was performed using SPSS Statistics 17.0.
Differences with a P value less than 0.05 were considered signiﬁcant,
and differences with a P value less than 0.01 were considered highly
signiﬁcant.
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